Connect with us

International Circuit

EU challenges Biden’s vaccine patent proposal

Europe indicated on Thursday that it won’t necessarily support President Biden’s proposal to waive patents on Covid-19 vaccines, creating an obstacle as some of the world’s poorest countries struggle to contain the latest wave of cases.

Under growing pressure, the European Union — whose approval would be needed — said Thursday it would consider the Biden administration’s decision. But the European Commission president, Ursula von der Leyen, said she did not endorse Mr. Biden’s plan, raising questions about whether the bloc would agree to waive patents. And Germany, the bloc’s de facto leader, said that the U.S. proposal could trigger “significant implications” for the production of vaccines.

“The limiting factor in vaccine manufacturing is production capacity and high quality standards, not patents,” a spokeswoman for Chancellor Angela Merkel of Germany said in the statement.

In her speech, Ms. von der Leyen said that the European Union was “ready to discuss any proposals that address the crisis in an effective and pragmatic manner.”

But she also suggested that the focus should instead be on getting more vaccines to countries that needed them by following the bloc’s example in permitting the ample export of doses. The United States has so far balked at that approach, keeping most doses produced domestically for use at home. “We call upon all vaccine-producing countries to allow export and to avoid measures that disrupt the supply chains,” Ms. von der Leyen said.

The two European statements emphasized the challenges of winning critical E.U. support for securing the patent waivers. Many experts feel the waivers are needed to step up the manufacturing of vaccines and get them to poorer parts of the world where inoculations have far lagged those of richer countries. The European Union is a major force within the World Trade Organization, where unanimous approval by member countries would be required for any proposal to waive patents.

The European Union — and the United States, until this week — have been major holdouts at the World Trade Organization over a joint proposal by India and South Africa to suspend some intellectual property protections, which could give drugmakers access to the trade secrets of how the vaccines are made.

As India recorded a single-day high in new coronavirus cases on Thursday, its vaccination campaign has been marred by shortages and states are competing against one another to get doses, limiting the government’s hope that the country can soon emerge from a devastating outbreak.

The Indian health ministry recorded about 410,000 cases in 24 hours, a new global high, and 3,980 deaths, the highest daily death toll in any country outside the United States. Experts believe the number of actual infections and deaths is much higher.

A second wave of infections exploded last month, and some Indian states reintroduced partial lockdowns, but daily vaccination numbers have fallen. The government said it had administered nearly two million vaccine doses on Thursday, far lower than the 3.5 million doses a day it reached in March. Over the past week, 1.6 million people on average were vaccinated daily in the country of 1.4 billion.

India’s pace of vaccinations has become a source of global concern as its outbreak devastates the nation and spreads into neighboring countries, and as a variant first identified there begins to be found around the world. The outbreak has prompted India to keep vaccine doses produced by its large drug manufacturing industry at home instead of exporting them, slowing down vaccination campaigns elsewhere.

In an effort to make doses more widely available within India, the authorities have allowed states and private health care providers to buy vaccines directly from manufacturers. But that has left state governments competing with one another for doses, and experts say it has added more troubles to a sluggish rollout. The authorities in Delhi, the capital, and several states have said they had to delay the expansion of vaccine access to younger age groups because of shortages.

India also lacks enough doses to meet the growing demand. Two domestic drug companies — the Serum Institute of India, which is manufacturing the vaccine developed by AstraZeneca, and Bharat Biotech, which is making its own vaccine — are producing fewer than 100 million doses per month.

About 3 percent of India’s population has been fully vaccinated, and 9.2 percent of people have received at least one dose. Experts say that, at the current rate, the country is unlikely to meet Prime Minister Narendra Modi’s target of inoculating 300 million people by August.

India has recorded 21 million coronavirus cases and more than 230,000 deaths, according to a New York Times database.

India’s government has said it will fast-track approvals of foreign-made vaccines, and on Wednesday the Biden administration said it would support waiving intellectual property protections for Covid-19 vaccines to increase supplies for lower-income countries.

But a waiver would need to win unanimous support at the World Trade Organization — and even then, experts say, India’s drug companies would need extensive technological and other support to produce doses.

“The drop in I.P. protections is only one element,” Anant Bhan, a health researcher at Melaka Manipal Medical College in southern India, said of intellectual property. Because of the additional steps required to begin making a vaccine on a huge scale, he said, “It is not going to mean increased access to vaccines in the near future.”

As Mr. Modi has declined to impose a nationwide lockdown like the one he brought in last year, states have adopted their own measures. On Thursday, the southern state of Kerala, which has one of the highest caseloads, announced a near-total lockdown until May 16.

Experts also worry that a crisis may be unfolding in India’s rural areas, where testing capacities are even more limited.

“My main concern is nonavailability of testing and the logistics of not getting people tested in rural areas,” said Gautam Menon, a professor of physics and biology at Ashoka University in northern India. “So we will never get the real numbers for either infection rates or deaths from many such quarters of India.”

The U.S. State Department has approved the departure of family members of U.S. government employees in India and is urging American citizens to take advantage of commercial flights out of the country. It said on Wednesday that it would approve the voluntary departure of nonemergency U.S. government employees.

On Thursday, Sri Lanka became the latest country to bar travelers from India, joining the United States, Britain, Australia and others. The New York Times

Copyright © 2024 Medical Buyer

error: Content is protected !!